Delay of appropriate antibiotic treatment is associated with high mortality in patients with community-onset sepsis in a Swedish setting.


Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 10 12 2018
accepted: 01 03 2019
pubmed: 27 3 2019
medline: 15 11 2019
entrez: 27 3 2019
Statut: ppublish

Résumé

Early appropriate antimicrobial therapy is crucial in patients with sepsis and septic shock. Studies often focus on time to first dose of appropriate antibiotics, but subsequent dosing is equally important. Our aim was to investigate the impact of fulfillment of early treatment, with focus on appropriate administration of first and second doses of antibiotics, on 28-day mortality in patients with community-onset severe sepsis and septic shock. A retrospective study on adult patients admitted to the emergency department with community-onset sepsis and septic shock was conducted 2012-2013. The criterion "early appropriate antibiotic treatment" was defined as administration of the first dose of adequate antibiotics within 1 h, and the second dose given with less than 25% delay after the recommended dose interval. A high-risk patient was defined as a septic patient with either shock within 24 h after arrival or red triage level on admittance according to the Medical Emergency Triage and Treatment System Adult. Primary endpoint was 28-day mortality. Of 90 patients, less than one in four (20/87) received early appropriate antibiotic treatment, and only one in three (15/44) of the high-risk patients. The univariate analysis showed a more than threefold higher mortality among high-risk patients not receiving early appropriate antibiotic treatment. Multivariable analysis identified early non-appropriate antibiotic treatment as an independent predictor of mortality with an odds ratio for mortality of 10.4. Despite that the importance of early antibiotic treatment has been established for decades, adherence to this principle was very poor.

Identifiants

pubmed: 30911928
doi: 10.1007/s10096-019-03529-8
pii: 10.1007/s10096-019-03529-8
pmc: PMC6570779
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1223-1234

Références

Clin Infect Dis. 2000 Apr;30(4):633-8
pubmed: 10770721
N Engl J Med. 2001 Nov 8;345(19):1368-77
pubmed: 11794169
Chest. 1992 Jun;101(6):1644-55
pubmed: 1303622
Crit Care. 2004 Aug;8(4):R153-62
pubmed: 15312213
Ann Emerg Med. 2005 May;45(5):524-8
pubmed: 15855951
Crit Care Med. 2005 Jul;33(7):1538-48
pubmed: 16003060
J Infect Dis. 2006 Jan 15;193(2):251-8
pubmed: 16362889
Ann Emerg Med. 2006 Nov;48(5):583-90, 590.e1
pubmed: 17052559
Crit Care Med. 2007 May;35(5):1284-9
pubmed: 17414725
Lakartidningen. 2008 Jan 23-29;105(4):201-4
pubmed: 18306820
JAMA. 2008 May 21;299(19):2294-303
pubmed: 18492971
J Emerg Med. 2011 Jun;40(6):623-8
pubmed: 18930373
Chest. 2009 Nov;136(5):1237-1248
pubmed: 19696123
Crit Care Med. 2010 Apr;38(4):1045-53
pubmed: 20048677
Intensive Care Med. 2010 Feb;36(2):222-31
pubmed: 20069275
Chest. 2011 May;139(5):1210-1220
pubmed: 21540219
Crit Care Med. 2011 Sep;39(9):2066-71
pubmed: 21572327
Am J Emerg Med. 2012 Oct;30(8):1447-56
pubmed: 22205015
Crit Care Med. 2012 Jul;40(7):2082-9
pubmed: 22584761
Intensive Care Med. 2013 Feb;39(2):165-228
pubmed: 23361625
Clin Microbiol Infect. 2013 Jun;19(6):501-9
pubmed: 23473333
Virulence. 2014 Jan 1;5(1):80-97
pubmed: 24184742
Clin Infect Dis. 2014 Apr;58(8):1072-83
pubmed: 24429437
BMC Infect Dis. 2014 Mar 04;14:121
pubmed: 24588984
JAMA. 2014 Apr 2;311(13):1308-16
pubmed: 24638143
Crit Care Med. 2014 Aug;42(8):1749-55
pubmed: 24717459
Adv Drug Deliv Rev. 2014 Nov 20;77:3-11
pubmed: 25038549
Crit Care Med. 2014 Oct;42(10):2211-8
pubmed: 25054672
Crit Care Med. 2015 Jan;43(1):13-21
pubmed: 25251760
Crit Care. 2014 Sep 09;18(5):503
pubmed: 25394679
Int J Antimicrob Agents. 2015 Apr;45(4):385-92
pubmed: 25656151
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Acta Anaesthesiol Scand. 2017 Feb;61(2):186-193
pubmed: 27699759
PLoS One. 2016 Nov 11;11(11):e0166527
pubmed: 27835663
Open Forum Infect Dis. 2016 Dec 8;3(4):ofw207
pubmed: 27942538
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Crit Care Med. 2017 Jun;45(6):956-965
pubmed: 28328652
N Engl J Med. 2017 Jun 8;376(23):2235-2244
pubmed: 28528569
PLoS One. 2017 Jul 18;12(7):e0181312
pubmed: 28719660
JAMA. 2017 Oct 3;318(13):1241-1249
pubmed: 28903154
J Emerg Med. 2017 Oct;53(4):588-595
pubmed: 28916120
Drugs. 2018 Mar;78(4):439-451
pubmed: 29476349
Int J Infect Dis. 2018 Jun;71:59-64
pubmed: 29649549
Clin Infect Dis. 2018 Oct 12;:null
pubmed: 30312362
J Intensive Care Soc. 2018 Nov;19(4):299-304
pubmed: 30515239
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239

Auteurs

Maria Andersson (M)

Division of Infectious Diseases, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. maria.ka.andersson@regionostergotland.se.

Åse Östholm-Balkhed (Å)

Division of Infectious Diseases, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.

Mats Fredrikson (M)

Occupational and Environmental Medicine, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Forum Östergötland, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.

Martin Holmbom (M)

Division of Infectious Diseases, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Urology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.

Anita Hällgren (A)

Division of Infectious Diseases, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.

Sören Berg (S)

Division of Cardiothoracic Anesthesia and Intensive Care, Department of Medicine and Health Science, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.

Håkan Hanberger (H)

Division of Infectious Diseases, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH